Fulgent Genetics, which offers genetic testing for over 7,500 conditions, raised $38 million by offering 4.2 million shares at $9, the low end of the range of $9 to $11. Fulgent originally planned to raise $60 million by offering 4.6 million shares at $12 to $14, but revised its range on Wednesday. The company plans to list on the Nasdaq under the symbol FLGT. Credit Suisse, Piper Jaffray and Raymond James acted as lead managers on the deal.
